“What if I do nothing?”

Who didn't have that thought cross their mind when diagnosed w/ cancer?

Interesting work by Jennifer Plichta MD (she/her) Shelley Hwang Duke Cancer

link.springer.com/article/10.100…

'Survival among patients with untreated metastatic breast cancer: ''What if I do nothing?''

Great #TumorBoardTuesday on hormone receptor negative, HER2low breast cancer.

Always some nice ‘nuggets’, figures, and review! Great work by Nerea Lopetegui-Lia, MD Margaret Gatti-Mays MD MPH FACP & the #TumorBoardTuesday team

Given the recent FDA accelerated approval of TDXd for advanced HER2 pos solid tumors, recognizing and managing TDXd induced ILD is increasingly relevant. And patient education is also critical!

📍In metastatic #TNBC , biopsy site matters! 📍

Things to keep in mind when trying to determine #IO benefit/eligibility

Nerea Lopetegui-Lia, MD Margaret Gatti-Mays MD MPH FACP Pelotonia Institute for Immuno-Oncology Ohio State Medical Oncology

📢 Join us for a fun discussion tonight, 4/16/2024 at 8PM ET as Margaret Gatti-Mays MD MPH FACP & I highlight some key aspects of HER2-low #MBC #bcsm

Excited to be in Chapel Hill today for UNC Lineberger Cancer Center Grand Rounds 💻🧬

But had to start my day with a run through the beautiful UNC campus & past the Old Well!

I’ve been struck by how differently we tx extracranial vs intracranial oligoPD. We default to SRS all the time for oligoPD in brain mets but not extracranial mets. And the reverse - we can be slow to defer RT in favor of switching systemic tx at times of high brain met velocity

I always learn something new from #TumorBoardTuesday - Excited to join tomorrow!

Margaret Gatti-Mays MD MPH FACP Nerea Lopetegui-Lia, MD The James Ohio State Medical Oncology

Excited to see Arya Roy co-leading this effort to help us understand & advance workforce diversity! Way to bring data to an important issue

And, so excited Arya Roy is joining The James Breast Onc Team this fall💯

CC: Margaret Gatti-Mays MD MPH FACP Sagar Sardesai Dionisia Quiroga, DO, PhD Nicole Williams MD

So excited to do #tumorboardtuesday with #RisingStar Nerea Lopetegui-Lia, MD ClevelandClinicNews and discuss #mBC #HER2low #bcsm The James Ohio State Medical Oncology on Tuesday 4/16

Amazing resource! Single cell atlas of breast cancer - can’t wait to check this out.

Congratulations to Isaac Chan, MD, PhD lab & collaborators incl Sangeetha Reddy Heather McArthur, MD, MPH Christine Hodgdon Evanthia Roussos Torres, MD, PhD UTSW Simmons Cancer Center !

#bcsm OncoAlert

So proud of Vishnu Prasath, MD, MS - an *amazing* PSTP house staff The Ohio State University College of Medicine who presented NCI9455 & correlatives as 1st author at #AACR2024 .

Still seeking to understand the RAS/MEK/ERK pathway & #TNBC ...but all data takes us one step closer.

The James Pelotonia The Ohio State University Wexner Medical Center

Wish I had been there to see this session! Can't think of a better trio, each of whom are doing amazing work on disparities - including The James' own Samilia Obeng-Gyasi, MD, MPH!

Come check out the exciting and innovative work Dionisia Quiroga, DO, PhD et al are doing in #TNBC ! Section 45/Poster 28 AACR #AACR24 The James #bcsm

Congratulations Hope Rugo! So well deserved

Our study on the prognosis of small TNBCs is out in npj Journals Breast. Among 8601 pts with stage I TNBC in SEER, we found excellent 5-year outcomes, with a significant BCSS benefit for chemo in pT1c. Benefit less clear in tumors ≤1cm: biomarkers needed! nature.com/articles/s4152…

Progress...but still more to go! ⬆️📈

Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases | NEJM OncoAlert nejm.org/doi/full/10.10…

📣What is the role of immune activation on the prognosis of early #TNBC if chemo is not given? We evaluated ~ 2,000 pts w eTNBC from 13 institutions around the globe to answer this. See our results published today in JAMA

jamanetwork.com/journals/jama/…

This is a critical need. Why is histologic subtype so rarely reported? Why so few subset analyses?

Thanks to Christine Desmedt and colleagues for highlighting this!

CC: Dr. Steffi Oesterreich Matthew J. Sikora, PhD